Cytarabine 100mg/ml injection 100mg/ml (10mL) Malta - English - Medicines Authority

cytarabine 100mg/ml injection 100mg/ml (10ml)

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cytarabine - solution for injection - cytarabine 100 mg/ml - antineoplastic agents

Cytarabine 100mg/ml injection Solution for Injection 100mg/ml (20mL) Malta - English - Medicines Authority

cytarabine 100mg/ml injection solution for injection 100mg/ml (20ml)

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cytarabine - solution for injection - cytarabine 100 mg/ml - antineoplastic agents

ARA-CELL 4 G Israel - English - Ministry of Health

ara-cell 4 g

mbi pharma ltd., israel - cytarabine - solution for infusion - cytarabine 4000 mg / 80 ml - cytarabine - ara-cell® 4000 mg is indicated for induction and maintenance of clinical remission in patients with acute myeloid leukemia, acute non-lymphoblastic leukemias, acute lymphoblastic leukemias, blast crises of chronic myeloid leukemia, diffuse histiocytic lymphomas (non-hodgkin's lymphomas of high malignancy).

ARA-CELL 4 G Israel - English - Ministry of Health

ara-cell 4 g

mbi pharma ltd., israel - cytarabine - solution for infusion - cytarabine 4000 mg / 80 ml - cytarabine - ara-cell® 4000 mg is indicated for induction and maintenance of clinical remission in patients with acute myeloid leukemia, acute non-lymphoblastic leukemias, acute lymphoblastic leukemias, blast crises of chronic myeloid leukemia, diffuse histiocytic lymphomas (non-hodgkin's lymphomas of high malignancy).

ARA-CELL 5 G Israel - English - Ministry of Health

ara-cell 5 g

mbi pharma ltd., israel - cytarabine - concentrate for solution for infusion - cytarabine 5 g / 50 ml - cytarabine - ara-cell® 100 mg/ml is used in combination with other cytostatic agents in high-dose therapy for:• refractory non-hodgkin’s lymphoma• refractory acute non-lymphocytic leukaemia• refractory acute lymphoblastic leukaemia• recurrent cases of acute leukaemia• types of leukaemia with special risk: – secondary leukaemia following previous chemotherapy and/or radiation treatment – manifest leukaemia following transformation of pre-leukaemia• consolidation of the remission of acute non-lymphocytic leukaemia in patients under 60 years of age.

ARA-CELL 5 G Israel - English - Ministry of Health

ara-cell 5 g

mbi pharma ltd., israel - cytarabine - concentrate for solution for infusion - cytarabine 5 g / 50 ml - cytarabine - ara-cell® 100 mg/ml is used in combination with other cytostatic agents in high-dose therapy for:• refractory non-hodgkin’s lymphoma• refractory acute non-lymphocytic leukaemia• refractory acute lymphoblastic leukaemia• recurrent cases of acute leukaemia• types of leukaemia with special risk: – secondary leukaemia following previous chemotherapy and/or radiation treatment – manifest leukaemia following transformation of pre-leukaemia• consolidation of the remission of acute non-lymphocytic leukaemia in patients under 60 years of age.